Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
about
Active surveillance and focal therapy for low-intermediate risk prostate cancerHistological outcomes after focal high-intensity focused ultrasound and cryotherapyProstate volume and biopsy tumor length are significant predictors for classical and redefined insignificant cancer on prostatectomy specimens in Japanese men with favorable pathologic features on biopsyProstate cancer tumour features on template prostate-mapping biopsies: implications for focal therapyDefining the level of evidence for technology adoption in the localized prostate cancer pathwayA prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT)Gleason 6 Prostate Cancer: Translating Biology into Population Health.Quantitative identification of magnetic resonance imaging features of prostate cancer response following laser ablation and radical prostatectomyPROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer.Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind? - The Cancer.Should Gleason 6 be labeled as cancer?A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study.Image-guided robotic interventions for prostate cancer.Health technology assessment in evolution - focal therapy in localised prostate cancer.Focal cryotherapy of localized prostate cancer: a systematic review of the literature.The challenging landscape of medical device approval in localized prostate cancer.High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.Does true Gleason pattern 3 merit its cancer descriptor?Prostate cancer: Melbourne consensus-noble but misguided.Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason gradeRole of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.Two-dimensional neovascular complexity is significantly higher in nontumor prostate tissue than in low-risk prostate cancer.Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.Prostate imaging--the future is now: current concepts and future potentials.[Focal therapy for prostate cancer: German version].Can we deliver randomized trials of focal therapy in prostate cancer?Multiparametric 3T MRI in the evaluation of intraglandular prostate cancer: correlation with histopathology.Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China.[Focal therapy of prostate cancer in Germany].Establishing implantation uncertainties for focal brachytherapy with I-125 seeds for the treatment of localized prostate cancer.Multidisciplinary Approach of Prostate Cancer PatientsProstate imaging features that indicate benign or malignant pathology on biopsyA Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer
P2860
Q26773641-F40E41CA-C3DD-44A7-A43F-0B43A3296DBAQ26820469-8E69F9C6-A296-4F25-9D0D-84907752978DQ33717988-865E8C6F-96D2-4622-A0C2-C0B81AF22EF6Q33775669-DEA56FEF-7C9F-4E1B-8BEF-B66A724ADB73Q34061419-0A95980C-B977-4216-8B29-911DD53B1F45Q34306878-AB038513-6252-4220-A92D-3D56D26ABCDBQ34470640-0B2733C3-E59B-4F64-9E77-5D2EE6C76AB7Q35686849-645A2467-CC73-4E84-B518-51836ACAEF38Q35700730-142D7C49-F524-4BCF-B901-AE1198DE5870Q36575721-442FD082-70B8-43BE-8A18-8B5DD7883E98Q36931932-F76B21F1-DCCC-4320-B829-97B946EC32BBQ37188309-92AE63C1-77A6-4B64-9D9F-A10A7F7D2365Q38115134-F0BF8446-B90A-4CD8-8DFE-39BC363A22AFQ38223247-6BD169BB-5C18-4AB2-BC2A-B5CDD1E767ADQ38264786-4111D23C-A468-407D-AB6B-2FACFE051B63Q38668993-8290F7EC-38F5-429D-97C6-89B3AE82FB7AQ38906488-6A1FA058-6EEB-41FE-8930-FE235AA0E5A5Q38928930-012A370A-F8F6-46C0-8224-B51E31E95FCAQ40179666-C2F0174F-9811-4A8D-9F34-49E570389E18Q40666530-7987866D-6C28-4496-935C-E655571D99EBQ40875442-5B5A87CC-CEDB-4EE4-B67B-516867B36F96Q42533906-5004EED0-E422-4CB6-AB51-BD676EA2B1F0Q43790447-1FB9D8F8-38BC-4748-A4FF-16547284284FQ48853490-83653A18-44B5-407E-B1A2-5BE14E27AA47Q50241890-A3F33DC0-F712-47A5-8B35-AB3C79D487D7Q50243071-969D670E-F889-49E7-B20A-299F754770D0Q51074429-2C3FAD24-D8B3-4A52-8608-8310ECCCA76CQ51242769-7A749B02-EE84-42BD-BAD0-979EFB03640CQ53108923-43C7450D-CCFB-4C56-97BE-E6F29BACA9B8Q53643281-2D48D102-7970-4FE7-A05D-91639B72C3AFQ57575087-593CD14D-1843-4E07-9AD5-996A742A29CAQ58562204-90315949-0806-4103-9434-8C3A54F35290Q58794132-1D083918-83F9-4023-8DC7-5961C9996FFC
P2860
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
@ast
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
@en
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
@nl
type
label
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
@ast
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
@en
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
@nl
prefLabel
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
@ast
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
@en
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
@nl
P2093
P1433
P1476
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
@en
P2093
Alex Freeman
Hashim Uddin Ahmed
Manit Arya
P304
P356
10.1016/S1470-2045(12)70388-1
P577
2012-11-01T00:00:00Z